Utilizing Autologous Multipotent Mesenchymal Stromal Cells and -Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial
Table 1
(a) Demographics of patients in the trial group. (b) Demographics of patients in the control group.
(a)
Case
1
2
70
81
34
2
0
1
0
1
II
13.5
0
2
1
61
87
26
3
3
2
1
0
II
19.1
0
3
1
59
86
28
3
0
1
0
1
III
13.5
1
4
2
71
60
25
2
0
1
2
1
III
4.9
0
5
2
72
72
32
2
0
1
3
1
III
11.3
1
6
1
68
86
28
2
1
1
0
1
III
13.2
0
7
1
67
102
32
1
1
1
0
1
III
6.0
1
8
1
68
80
25
1
0
1
2
1
II
50.0
0
9
2
70
73
30
2
0
1
2
1
II
16.0
1
(b)
Case
1
1
68
94
31
1
0
1
0
1
II
13.5
1
2
2
68
87
31
1
0
1
1
0
II
18.75
0
3
2
66
86
33
1
0
1
2
1
II
15.0
0
4
2
75
54
20
1
0
1
0
1
II
22.5
0
5
2
70
93
32
1
1
3
1
2
II
12.0
0
6
2
70
70
27
2
1
1
2
1
II
24.0
0
7
2
69
83
31
2
0
1
0
1
II
10.5
1
8
2
75
78
29
1
1
1
0
1
IV
16.0
1
9
2
65
73
30
2
0
1
2
1
II
16.0
1
: gender: 1: male; 2: female; : age at revision (years); : weight (kg); : body mass index (kg/m2); : primary diagnosis: 1: osteoarthritis, 2: hip dysplasia, and 3: osteonecrosis; : number of previous revisions; : revision indication: 1: aseptic loosening, 2: instability of arthroplasty, and 3: suspected septic loosening (negative cultures); : cup revision: 0: none, 1: uncemented cup, 2: uncemented cup + morselized allogeneic bone graft, and 3: cemented cup + Burch Schneider + morselized allogeneic bone graft; : femoral component removed: 0: well-fixed and positioned femoral component not removed, 1: cemented, and 2: cement spacer; : AAOS defect classification: II: cavitary, III: combined segmental and cavitary, IV: malalignment, : size of the defect (cm3); : femoral reinforcement: 0: none and 1 cerclage strips.
